메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Kim Hyun-Young (Department of Laboratory Medicine and Genetics Samsung Medical Center Sungkyunkwan University Schoo) Yoo In Young (Department of Laboratory Medicine Seoul St. Mary's Hospital College of Medicine The Catholic Univer) Lim Dae Jin (Department of Laboratory Medicine and Genetics Samsung Medical Center Sungkyunkwan University Schoo) Kim Hee-Jin (Department of Laboratory Medicine and Genetics Samsung Medical Center Sungkyunkwan University Schoo) Kim Sun-Hee (Department of Laboratory Medicine and Genetics Samsung Medical Center Sungkyunkwan University Schoo) Yoon Sang Eun (Division of Hematology-Oncology Department of Medicine Samsung Medical Center Sungkyunkwan Universi) Kim Seok Jin (Division of Hematology-Oncology Department of Medicine Samsung Medical Center Sungkyunkwan Universi) Cho Duck (Department of Laboratory Medicine and Genetics Samsung Medical Center Sungkyunkwan University Schoo) Kim Kihyun (Division of Hematology-Oncology Department of Medicine Samsung Medical Center Sungkyunkwan Universi)
저널정보
대한진단검사의학회 Annals of Laboratory Medicine Annals of Laboratory Medicine 제42권 제5호
발행연도
2022.9
수록면
558 - 565 (8page)
DOI
10.3343/alm.2022.42.5.558

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Minimal residual disease (MRD) is an important prognostic factor for evaluating a deeper treatment response in patients with multiple myeloma (MM). We evaluated the clinical utility of next-generation flow (NGF)-based MRD assessment in a heterogeneous MM patient population. Methods: Patients with suspected morphological remission after or during MM treatment were prospectively enrolled. In total, 108 bone marrow samples from 90 patients were analyzed using NGF-based MRD assessment according to the EuroFlow protocol, and progression-free survival (PFS) was evaluated according to the International Myeloma Working Group response status, cytogenetic risk, and MRD status. Results: The overall MRD-positive rate was 31.5% (34/108 samples), and MRD-positive patients showed a lower PFS than MRD-negative patients (P=0.005). MRD-positive patients showed inferior PFS than MRD-negative in patients with stringent complete remission (sCR)/complete remission (P=0.014) and high-risk cytogenetic abnormalities (P=0.016). MRD was assessed twice in 18 patients with a median interval of 12 months. Sustained MRD negativity was only observed in patients with sustained sCR, and their PFS was superior to that of patients who were not MRD-negative (P=0.035). Conclusions: Clinical application of NGF-based MRD assessment can provide valuable information for predicting disease progression in patients with MM in remission, including those with high-risk cytogenetic abnormalities.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0